Aussie slips ahead of Chinese data

The Australian dollar has lost ground versus the US dollar ahead of the Chinese manufacturing purchasing managers' index (PMI) report.

The Aussie is trading down 0.1% at $0.9431, because traders are cautious ahead of the HSBC China PMI on Monday. China is the main destination for minerals exported from Australia, so the level of manufacturing activity in China is key for the Australian economy. The report came in at 50.1 in August. Any reading above 50.0 indicates an expansion, and if the September report is also strong we could see the aussie dollar move towards the $0.95 level.

The Aussie had been boosted by the US Federal Reserve's decision to keep US monetary policy unchanged instead of trimming the bond buying scheme as expected. In response, dealers bought the Australian currency and sold the US dollar, as the Fed’s policy keeps the US dollar in a relatively weak position. 

 

Spot FX AUD/USD chart

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.